The WHO is evaluating Mapp Biopharmaceutical's experimental MBP134 antibody as a potential standalone treatment for Bundibugyo Ebola, as well as testing its combination with Gilead Sciences' remdesivir antiviral drug.
Severity: 4.5/10Source: The HinduLocation: null, null